XEN1101

potassium channel opener with the same mechanism of action as retigabine

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Partial Epilepsies (Epilepsy, Partial) 11/01/2023 - "Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial." 12/01/2022 - "For adult focal epilepsies, padsevonil and carisbamate are at a more advanced Phase III stage of clinical development followed by compounds at Phase II like selurampanel, XEN1101 and JNJ-40411813. "
2.	Seizures (Absence Seizure) 11/01/2023 - "To evaluate the efficacy and safety of XEN1101, a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener, in the treatment of focal-onset seizures (FOSs). "
3.	Epilepsy (Aura) 11/01/2019 - "XEN1101 is a novel potassium channel opener undergoing clinical development for treatment of epilepsy. "

1.	Potassium Channels (Potassium Channel)
2.	KCNQ3 Potassium Channel
3.	S-2-O-carbamoyl-1-o-chlorophenyl-ethanol
4.	padsevonil
5.	1- butyl- 3- chloro- 4- (4- phenyl- 1- piperidinyl)- (1H)- pyridone
6.	selurampanel